original ) (raw )A Randomized, Open, Parallel Group, Multicenter Trial to Investigate Analgesic Efficacy and Safety of a New Transdermal Fentanyl Patch Compared to Standard Opioid Treatment in Cancer Pain
Hans Kress
Journal of Pain and Symptom Management, 2008
View PDFchevron_right
The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain
Keunchil Park
The Korean journal of internal medicine, 2015
View PDFchevron_right
High-Dose Fentanyl Patch for Cancer Pain
Pesach Shvartzman
The Journal of the American Board of Family Medicine, 2004
View PDFchevron_right
Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish oncology group trial
Mehmet Kömürcü
European Journal of Cancer Care, 2007
View PDFchevron_right
Transdermal fentanyl in the management of cancer pain in ambulatory patients: An open-label pilot study
Raylene Rospond , Julie Hammack
Journal of Pain and Symptom Management, 1996
View PDFchevron_right
Prospective clinical evaluation of transdermal fentanyl for the treatment of cancer pain
Laura Cerezo
2000
View PDFchevron_right
Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers
John Kouvaris
The Journal of Pain, 2004
View PDFchevron_right
Long-Term Treatment of Cancer Pain With Transdermal Fentanyl
Michael Zenz
Journal of Pain and Symptom Management, 1998
View PDFchevron_right
Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial
Naohito Shimoyama
International journal of clinical oncology, 2015
View PDFchevron_right
Compliance, efficacy and quality of life for oral morphine versus transdermal fentanyl patch in management of cancer pain
Dipankar Dakua
International Journal of Research in Medical Sciences
View PDFchevron_right
Treatment of Severe Cancer Pain by Transdermal Fentanyl
Samir Husic
Bosnian Journal of Basic Medical Sciences, 2010
View PDFchevron_right
Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period
Anna Orońska , Hans Kress
Clinical Therapeutics, 2009
View PDFchevron_right
Compliance for Transdermal Fentanyl Patch versus Sustained Release Oral Morphine in Cancer Pain
neena raizada
International Journal of Contemporary Medical Research [IJCMR], 2018
View PDFchevron_right
Oral Transmucosal Fentanyl Citrate: Randomized, Double-Blinded, Placebo-Controlled Trial for Treatment of Breakthrough Pain in Cancer Patients
James F Cleary
JNCI Journal of the National Cancer Institute, 1998
View PDFchevron_right
Poor adhesion of fentanyl transdermal patches may mimic end-of-dosage failure after 48 hours and prompt early patch replacement in hospitalized cancer pain patients
Isabelle Arnet
Journal of Pain Research
View PDFchevron_right
Efficacy of Fentanyl Transdermal Patch in the Treatment of Chronic Soft Tissue Cancer Pain
Farnad Imani
Anesthesiology and Pain Medicine, 2015
View PDFchevron_right
Clinical Efficacy of Transdermal Fentanyl in Adults with Cancer-Related Pain: An Open Multicentre Study
Yavuz Dizdar
Turkiye Klinikleri Journal of Medical Sciences, 2009
View PDFchevron_right
Managing Breakthrough Pain: A Clinical Review With Three Case Studies Using Oral Transmucosal Fentanyl Citrate
Guadalupe Palos
Clinical Journal of Oncology Nursing, 2004
View PDFchevron_right
Role of intranasal fentanyl in breakthrough pain management in cancer patients
Wojciech Leppert
Cancer Management and Research, 2010
View PDFchevron_right
Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study
Anna Crispo
Journal of Clinical Medicine, 2020
View PDFchevron_right
Long-Term Safety of Oral Transmucosal Fentanyl Citrate for Breakthrough Cancer Pain
Michael P Busch
Journal of Pain and Symptom Management, 2001
View PDFchevron_right
Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain
L. Haazen
The Journal of Pain, 2001
View PDFchevron_right
Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl
Kyriaki Mystakidou
International Journal of Cancer, 2003
View PDFchevron_right
Transdermal fentanyl for pain control in patients with cancer
James Miser
Pain, 1989
View PDFchevron_right
Fentanyl by Continuous Subcutaneous Infusion for the Management of Cancer Pain
Jose Pereira
Journal of Pain and Symptom Management, 1998
View PDFchevron_right
Long-term use of a once-a-day fentanyl citrate transdermal patch in lung cancer patients
Akio Niimi
Oncology Letters, 2015
View PDFchevron_right
Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study
Michael P Busch
PAIN, 1999
View PDFchevron_right
Transdermal fentanyl treatment in opioid-naïve cancer patients
PIlar Zamora
Clinical and …, 2003
View PDFchevron_right
Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses
Federica Aielli
Current Medical Research and Opinion, 2012
View PDFchevron_right
Fentanyl for the treatment of tumor-related breakthrough pain
Helmar Bornemann-Cimenti
2013
View PDFchevron_right
Danish Pain Specialists' Rationales behind the Choice of Fentanyl Transdermal Patches and Oral Transmucosal SystemsâA Delphi Study
Ramune Jacobsen , Lona Christrup
Pain Medicine, 2009
View PDFchevron_right
Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
Vicente De Sanctis
Drugs in R&D
View PDFchevron_right